Pembrolizumab Plus Bevacizumab vs Pembrolizumab Alone for Recurrent Glioblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Randomized Phase II and Biomarker Study of Pembrolizumab Plus Bevacizumab Versus Pembrolizumab Alone for Recurrent Glioblastoma Patients
Clin. Cancer Res 2020 Nov 16;[EPub Ahead of Print], L Nayak, AM Molinaro, KB Peters, JL Clarke, JT Jordan, JF de Groot, PL Nghiemphu, TJ Kaley, H Colman, C McCluskey, S Gaffey, T Smith, DJ Cote, M Severgnini, JH Yearley, Q Zhao, WM Blumenschein, DG Duda, A Muzikansky, RK Jain, PY Wen, DA ReardonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.